ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 308 for:    complementary and alternative medicine

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00949390
Recruitment Status : Completed
First Posted : July 30, 2009
Last Update Posted : April 7, 2016
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

Primary Objective:

· The primary objective is to estimate the prevalence of use of complementary and alternative medicine (CAM) in patients with advanced malignancies who are seen in the Phase I clinic at MD Anderson Cancer Center (MDACC).

Secondary Objective:

· Examine the association between prevalence of CAM use and demographic and socioeconomic characteristics (age, gender, race, income, and education level), participation in a phase I clinical trial, disease characteristics (diagnosis), patients' perceptions about their prognosis, physicians' information and permission for patients' CAM use, decision-making, and types of CAM used by patients.


Condition or disease Intervention/treatment
Advanced Cancer Behavioral: Questionnaire

Detailed Description:

This survey study is intended to estimate the prevalence of use of CAM in patients who are currently being treated in the Phase I Clinical Trials Program at University of Texas MD Anderson Cancer Center. The survey includes questions about socioeconomic characteristics (age, gender, race, income, and education level), patients' diagnosis and patients' perceptions about their prognosis, physicians' information and permission for patients' use of CAM, patients' use of CAM (yes or no), decision-making (purpose of CAM use), resources and types of CAM.

Patients will be asked to drop the questionnaire into a box in a specified location after completion of the questionnaire. Accrual is expected to be 50-100 patients per month. This survey is expected to finish in 6 months.


Study Type : Observational
Actual Enrollment : 309 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials
Study Start Date : July 2009
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Group/Cohort Intervention/treatment
Phase I and CAM Survey
Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
Behavioral: Questionnaire
Survey given at appointment time, then dropped in specified box anonymously.




Primary Outcome Measures :
  1. Prevalence of CAM use among patients enrolled in Phase I clinical trials (Questionnaire Response Rate) [ Time Frame: 1 Year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Current participation in a UT MDACC Phase I Clinical trial with a clinical diagnosis of advanced malignancy.
Criteria

Inclusion Criteria:

1) Patients with a clinical diagnosis of malignancy who are seen in the outpatient oncology clinic.

Exclusion Criteria:

1) Presence of any clinically relevant condition that, in the opinion of the investigator/ coordinator, would interfere with completing the study including, but not limited to, visual problems, cognitive impairment or acute mental illness.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00949390


Locations
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Aung Naing, MD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00949390     History of Changes
Other Study ID Numbers: 2009-0369
First Posted: July 30, 2009    Key Record Dates
Last Update Posted: April 7, 2016
Last Verified: April 2016

Keywords provided by M.D. Anderson Cancer Center:
Advanced Cancer
Advanced Malignancy
Complementary and Alternative Medicine
CAM
Investigational Cancer Therapeutics
Phase I Clinical Trials